Fetroja

Chemical Namecefiderocol
Dosage FormInjectable (intravenous; 1 g/vial)
Drug ClassAntibacterials
SystemUrinary
CompanyShionogi Inc.
Approval Year2019

Indication

  • Fetroja is indicated in patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by susceptible Gram-negative microorganisms.
Last updated on 12/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fetroja (cefiderocol) Prescribing Information2019Shionogi